Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression
Status:
RECRUITING
Trial end date:
2026-08-31
Target enrollment:
Participant gender:
Summary
This study investigates the impact of perioperative inhibition of beta-adrenergic and COX-2 signaling in ovarian cancer patients undergoing debulking surgery. The trial aims to assess the feasibility, safety, and biological effects of a combination of propranolol and etodolac in reducing cancer metastasis and improving immune responses.
Phase:
PHASE2
Details
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Collaborators:
National Cancer Institute (NCI) The Chaim Sheba Medical Center